Jyant Technologies, Inc.
Records under this name other than the patents Jyant Technologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Jyant Technologies, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,058,093 | Nanoformulations for Plants Lapsed on the fee record Ended Aug 28, 2026 · High confidence | Lapsed on the fee record | Ended Aug 28, 2026 | High confidence |
| US 8,796,422 | Chemokine-Immunoglobulin Fusion Polypeptides, Compositions, Method of Making and Use Thereof Lapsed on the fee record Ended Aug 5, 2026 · High confidence | Lapsed on the fee record | Ended Aug 5, 2026 | High confidence |
| US 8,231,907 | Novel Nanoparticles for Delivery of Active Agents Lapsed on the fee record Ended Jul 31, 2024 · High confidence | Lapsed on the fee record | Ended Jul 31, 2024 | High confidence |
| US 9,249,204 | Chemokine-Immunoglobulin Fusion Polypeptides, Compositions, Method of Making and Use Thereof Lapsed on the fee record Ended Feb 2, 2024 · High confidence | Lapsed on the fee record | Ended Feb 2, 2024 | High confidence |
| US 8,512,701 | ANTI-CXCL13 and ANTI-CXCR5 Antibodies for the Prevention and Treatment of Cancer and Cancer Cell Migration Term ended Term ended Jan 24, 2024 · Medium confidence | Term ended | Term ended Jan 24, 2024 | Medium confidence |
| US 9,233,120 | ANTI-CCL25 and ANTI-CCR9 Antibodies for the Prevention and Treatment of Cancer and Cancer Cell Migration Lapsed on the fee record Ended Jan 12, 2024 · Low confidence | Lapsed on the fee record | Ended Jan 12, 2024 | Low confidence |
| US 8,097,250 | Anti-Chemokine and Associated Receptors Antibodies for Inhibition of Growth of Neoplasms Term ended Term ended Nov 14, 2023 · Medium confidence | Term ended | Term ended Nov 14, 2023 | Medium confidence |
| US 8,563,476 | ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 and ANTI-CXCR5 Agents for Inflammatory Disorders Term ended Term ended Nov 14, 2023 · High confidence | Term ended | Term ended Nov 14, 2023 | High confidence |
| US 8,658,377 | Detecting Cancer with ANTI-CCL25 and ANTI-CCR9 Antibodies Term ended Ended no later than Nov 14, 2023 · Low confidence | Term ended | Ended no later than Nov 14, 2023 | Low confidence |
| US 7,964,194 | Anti-Chemokine and Associated Receptor Antibodies and Uses for Inhibition of Inflammation Lapsed on the fee record Ended Jun 21, 2023 · High confidence | Lapsed on the fee record | Ended Jun 21, 2023 | High confidence |